178 related articles for article (PubMed ID: 6341856)
21. Renin vs. angiotensin-converting enzyme inhibition in the rat: consequences for plasma and renal tissue angiotensin.
Allan DR; Hui KY; Coletti C; Hollenberg NK
J Pharmacol Exp Ther; 1997 Nov; 283(2):661-5. PubMed ID: 9353383
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
[TBL] [Abstract][Full Text] [Related]
23. Intrarenal renin inhibition increases renal function by an angiotensin II-dependent mechanism.
Siragy HM; Lamb NE; Rose CE; Peach MJ; Carey RM
Am J Physiol; 1988 Oct; 255(4 Pt 2):F749-54. PubMed ID: 3052111
[TBL] [Abstract][Full Text] [Related]
24. The first Sir George Pickering memorial lecture. Which inhibitors will give us true insight into what renin really does?
Haber E
J Hypertens; 1984 Jun; 2(3):223-30. PubMed ID: 6099385
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin.
Agarwal NS; Rich DH
J Med Chem; 1986 Dec; 29(12):2519-24. PubMed ID: 3783611
[TBL] [Abstract][Full Text] [Related]
26. Renin inhibitors containing a pyridyl amino diol derived C-terminus.
Heitsch H; Henning R; Kleemann HW; Linz W; Nickel WU; Ruppert D; Urbach H; Wagner A
J Med Chem; 1993 Sep; 36(19):2788-800. PubMed ID: 8410992
[TBL] [Abstract][Full Text] [Related]
27. Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Boger J; Poe M; LaMont BI; Lynch RJ; Ulm EH; Vlasuk GP
J Med Chem; 1987 Oct; 30(10):1853-7. PubMed ID: 3309316
[TBL] [Abstract][Full Text] [Related]
28. In vitro inhibition of human renin by statine-containing tripeptide renin inhibitor (ES-1005).
Kokubu T; Hiwada K; Murakami E; Muneta S; Morisawa Y; Yabe Y; Koike H; Iijima Y
J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S88-90. PubMed ID: 2485069
[TBL] [Abstract][Full Text] [Related]
29. Will renin inhibitors influence decision-making in antihypertensive therapy?
Haber E
J Hypertens Suppl; 1985 Nov; 3(2):S71-80. PubMed ID: 3003303
[TBL] [Abstract][Full Text] [Related]
30. Peptides as targets for antihypertensive drug development.
Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of all the stereoisomers of statine (4-amino-3-hydroxy-6-methylheptanoic acid). Inhibition of pepsin activity by N-carbobenzoxy-L-valyl-L-valyl-statine derived from the four stereoisomers.
Liu WS; Smith SC; Glover GI
J Med Chem; 1979 May; 22(5):577-9. PubMed ID: 379333
[TBL] [Abstract][Full Text] [Related]
32. On the specificity of human renin. Studies with peptide inhibitors.
Poulsen K; Haber E; Burton J
Biochim Biophys Acta; 1976 Dec; 452(2):533-7. PubMed ID: 1009126
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydroxy-7-methyloctanoic acid.
Johnson RL; Verschoor K
J Med Chem; 1983 Oct; 26(10):1457-62. PubMed ID: 6352942
[TBL] [Abstract][Full Text] [Related]
34. [The renin-angiotensin system and its inhibition (author's transl)].
Corvol P; Elkik F; Thibonnier M; Plouin PF; Menard J
Nouv Presse Med; 1981 Apr; 10(19):1525-30. PubMed ID: 6269554
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a potent inhibitor of subprimate and primate renins.
Wood JM; Mah SC; Baum HP; de Gasparo M; Cumin F; Rüeger H; Nussberger J
J Pharmacol Exp Ther; 1990 May; 253(2):513-7. PubMed ID: 2110974
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of renin and their utility in physiologic studies.
Haber E; Burton J
Fed Proc; 1979 Dec; 38(13):2768-73. PubMed ID: 510563
[TBL] [Abstract][Full Text] [Related]
37. Highly potent and specific inhibitors of human renin.
Kokubu T; Hiwada K; Murakami E; Imamura Y; Matsueda R; Yabe Y; Koike H; Iijima Y
Hypertension; 1985; 7(3 Pt 2):I8-11. PubMed ID: 2987128
[TBL] [Abstract][Full Text] [Related]
38. Pepstatin inhibition mechanism.
Marciniszyn J; Hartsuck JA; Tang J
Adv Exp Med Biol; 1977; 95():199-210. PubMed ID: 339690
[TBL] [Abstract][Full Text] [Related]
39. Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.
Rosenberg SH; Plattner JJ; Woods KW; Stein HH; Marcotte PA; Cohen J; Perun TJ
J Med Chem; 1987 Jul; 30(7):1224-8. PubMed ID: 3298652
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
Sweet CS
Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
